(MDGL) Madrigal Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 11.817m USD | Total Return: 89.2% in 12m
Avg Turnover: 126M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 31.4% YoY
Interest Coverage Ratio -10.8 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -6.39 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Madrigal Pharmaceuticals (MDGL) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH). Its primary product, Rezdiffra, is a once-daily oral medication designed to target thyroid hormone receptor beta in the liver to reduce fat accumulation and inflammation.
The company operates within the biotechnology sector, which is characterized by high research and development costs and a heavy reliance on regulatory approvals from the FDA. MASH represents a significant unmet medical need, as it is a leading cause of liver transplantation and often lacks standardized pharmacological treatment options.
Investors can further evaluate the companys long-term valuation and pipeline potential by visiting ValueRay. Madrigal is headquartered in West Conshohocken, Pennsylvania, and focuses its commercial efforts on the United States market.
- Rezdiffra commercial adoption rates and insurance coverage expansion drive near-term revenue
- Payer reimbursement negotiations and prior authorization hurdles impact patient access
- Expansion of MASH diagnostic testing increases the addressable patient population
- Competition from emerging GLP-1 and FGF21 therapies threatens long-term market share
- Regulatory approval timeline for international markets dictates geographic revenue diversification
| Net Income: -309.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 18.08 > 1.0 |
| NWC/Revenue: 74.53% < 20% (prev 258.6%; Δ -184.1% < -1%) |
| CFO/TA -0.22 > 3% & CFO -268.1m > Net Income -309.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.0m) vs 12m ago 31.42% < -2% |
| Gross Margin: 93.07% > 18% (prev 0.97%; Δ 9.21k% > 0.5%) |
| Asset Turnover: 101.8% > 50% (prev 31.85%; Δ 70.00% > 0%) |
| Interest Coverage Ratio: -10.78 > 6 (EBITDA TTM -287.6m / Interest Expense TTM 26.8m) |
| A: 0.69 (Total Current Assets 1.18b - Total Current Liabilities 338.3m) / Total Assets 1.23b |
| B: -1.78 (Retained Earnings -2.18b / Total Assets 1.23b) |
| C: -0.26 (EBIT TTM -289.1m / Avg Total Assets 1.11b) |
| D: -3.19 (Book Value of Equity -2.18b / Total Liabilities 683.9m) |
| Altman-Z'' = -6.39 = D |
| DSRI: 0.85 (Receivables 187.4m/61.4m, Revenue 1.13b/317.4m) |
| GMI: 1.04 (GM 93.07% / 96.61%) |
| AQI: 5.39 (AQ_t 0.03 / AQ_t-1 0.00) |
| SGI: 3.57 (Revenue 1.13b / 317.4m) |
| TATA: -0.03 (NI -309.4m - CFO -268.1m) / TA 1.23b) |
| Beneish M = 1.30 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 513.59 with a total of 201,606 shares traded.
Over the past week, the price has changed by -1.23%,
over one month by -2.25%,
over three months by +18.15% and
over the past year by +89.23%.
Madrigal Pharmaceuticals has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy MDGL.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 674.4 | 31.3% |
P/S = 10.4349
P/B = 21.7887
Revenue TTM = 1.13b USD
EBIT TTM = -289.1m USD
EBITDA TTM = -287.6m USD
Long Term Debt = 340.3m USD (from longTermDebt, last quarter)
Short Term Debt = 1.70m USD (from shortTermDebt, last quarter)
Debt = 354.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.98m
Net Debt = -463.6m USD (calculated: Debt 354.3m - CCE 817.9m)
Enterprise Value = 11.4b USD (11.8b + Debt 354.3m - CCE 817.9m)
Interest Coverage Ratio = -10.78 (Ebit TTM -289.1m / Interest Expense TTM 26.8m)
EV/FCF = -41.68x (Enterprise Value 11.4b / FCF TTM -272.4m)
FCF Yield = -2.40% (FCF TTM -272.4m / Enterprise Value 11.4b)
FCF Margin = -24.05% (FCF TTM -272.4m / Revenue TTM 1.13b)
Net Margin = -27.32% (Net Income TTM -309.4m / Revenue TTM 1.13b)
Gross Margin = 93.07% ((Revenue TTM 1.13b - Cost of Revenue TTM 78.5m) / Revenue TTM)
Gross Margin QoQ = 91.38% (prev 92.39%)
Tobins Q-Ratio = 9.25 (Enterprise Value 11.4b / Total Assets 1.23b)
Interest Expense / Debt = 7.57% (Interest Expense 26.8m / Debt 354.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -228.4m (EBIT -289.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.50 (Total Current Assets 1.18b / Total Current Liabilities 338.3m)
Debt / Equity = 0.65 (Debt 354.3m / totalStockholderEquity, last quarter 543.5m)
Debt / EBITDA = 1.61 (negative EBITDA) (Net Debt -463.6m / EBITDA -287.6m)
Debt / FCF = 1.70 (negative FCF - burning cash) (Net Debt -463.6m / FCF TTM -272.4m)
Total Stockholder Equity = 617.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.83% (Net Income -309.4m / Total Assets 1.23b)
RoE = -11.04% (Net Income TTM -309.4m / Total Stockholder Equity 2.80b)
RoCE = -9.20% (EBIT -289.1m / Capital Employed (Equity 2.80b + L.T.Debt 340.3m))
RoIC = -29.76% (negative operating profit) (NOPAT -228.4m / Invested Capital 767.6m)
WACC = 9.73% (E(11.8b)/V(12.2b) * Re(9.84%) + D(354.3m)/V(12.2b) * Rd(7.57%) * (1-Tc(0.21)))
Discount Rate = 9.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 18.65%
[DCF] Fair Price = unknown (Cash Flow -272.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.27 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.59 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.23 | Chg30d=-58.38% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-1.03 | Chg30d=-69.39% | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=-6.52 | Chg30d=-12.82% | Revisions=+0% | GrowthEPS=+48.7% | GrowthRev=+56.1%
EPS next Year (2027-12-31): EPS=12.38 | Chg30d=-3.24% | Revisions=+14% | GrowthEPS=+289.8% | GrowthRev=+47.5%
[Analyst] Revisions Ratio: -20%